Novo, Lilly shares sink due to concerns over competition

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hellloooooo. Today, we discuss the FDA’s lack of engagement with critics of MDMA for PTSD therapy. We also highlight a massive veterans study on genomics, and how it illustrates the importance of studying diverse populations. And there’s more.

FDA silent on claims of misconduct in MDMA trials

At last month’s advisory committee meeting about Lykos Therapeutics’ MDMA-assisted therapy, the FDA said that it would investigate allegations of data suppression and misconduct in trials of the treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In